Breaking News

Novartis Makes Offer for French CDMO

Proposed acquisition builds on existing agreement with CellforCure for contract manufacturing of Novartis' leading CAR-T cell therapy Kymriah

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Novartis has made an offer to acquire CellforCure from LFB. CellforCure, a French company, is one of the first and largest contract development and manufacturing organizations (CDMO) producing cell and gene therapies in Europe.   Under the proposed agreement, Novartis would acquire the share capital of CellforCure from LFB including the cell and gene manufacturing facility located in Les Ulis and the related adjacent land. If the offer is accepted, CellforCure would become a wholly owned Novar...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters